Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11026 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Anastasilakis, A. D., Papapoulos S. E., Polyzos S. A., Appelman-Dijkstra N. M., & Makras P. (2019).  Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.. J Bone Miner Res.
Anastasilakis, A. D., Polyzos S. A., Tsoli M., Papatheodorou A., Kokkoris P., Kaltsas G., et al. (2017).  Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity.. Metabolism. 71, 198-201.
Anastasilakis, A. D., Polyzos S. A., & Nikolopoulos P. (2008).  Subendothelial carotid hematoma after fine-needle aspiration biopsy of a solitary thyroid nodule.. J Ultrasound Med. 27(10), 1517-20.
Anastasilakis, A. D., Makras P., Doulgeraki A., Polyzos S. A., Guarnieri V., & Papapoulos S. E. (2021).  Denosumab for the treatment of primary pediatric osteoporosis.. Osteoporos Int.
Anastasilakis, A. D., Polyzos S. A., Rodopaios N. E., Makras P., Kumar A., Kalra B., et al. (2022).  Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study.. Metabolism. 141, 155397.
Anastasilakis, A. D., Koulaxis D., Kefala N., Polyzos S. A., Upadhyay J., Pagkalidou E., et al. (2017).  Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD. Metabolism. 73, 1-8.
Anastasilakis, A. D., Ruggeri R-M., Polyzos S. A., Makras P., Molyva D., Campennì A., et al. (2013).  Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literature.. Metabolism. 62(10), 1350-6.
Anastasilakis, A. D., Makras P., Paccou J., Bisbinas I., Polyzos S. A., & Papapoulos S. E. (2023).  Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab.. J Clin Med. 12(18), 
Anastasilakis, A. D., Tournis S., Yavropoulou M. P., Polyzos S. A., & Makras P. (2018).  Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. Calcif Tissue Int. 103(1), 107-108.
Anastasilakis, A. D., Polyzos S. A., Savvidis M., Anastasilakis D. A., Sarridimitriou A., Kumar A., et al. (2023).  Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study.. Endocrine. 81(3), 573-578.
Anastasilakis, A. D., Toulis K. A., Nisianakis P., Goulis D. G., Kampas L., Valeri R-M., et al. (2012).  Selenomethionine treatment in patients with autoimmune thyroiditis: a prospective, quasi-randomised trial.. Int J Clin Pract. 66(4), 378-83.
Anastasilakis, A. D., Polyzos S. A., Skouvaklidou E. C., Kynigopoulos G., Saridakis Z. G., Apostolou A., et al. (2016).  Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans.. Metabolism. 65(10), 1459-65.
Anastasilakis, A. D., Toulis K. A., Polyzos S. A., Anastasilakis C. D., & Makras P. (2012).  Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab.. Ther Clin Risk Manag. 8, 295-306.
Anastasilakis, A. D., Goulis D. G., Polyzos S. A., Gerou S., Ballaouri I., Efstathiadou Z., et al. (2009).  No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.. Clin Endocrinol (Oxf). 70(4), 522-6.
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., Ntenti C., Mandanas S., & Makras P. (2021).  Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.. Endocrine.
Anastasilakis, A. D., Polyzos S. A., Anastasilakis C. D., Toulis K. A., & Makras P. (2011).  Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesis.. Med Hypotheses. 77(1), 109-11.
Anastasilakis, A. D., Polyzos S. A., Avramidis A., Toulis K. A., Papatheodorou A., & Terpos E. (2010).  The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.. Clin Endocrinol (Oxf). 72(6), 752-7.
Anastasilakis, A. D., Papachatzopoulos S., Makras P., Gkiomisi A., Nikolakopoulos P., Polyzos S. A., et al. (2022).  The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis.. Bone. 158, 116354.
Anastasilakis, A. D., Goulis D. G., Polyzos S. A., Gerou S., Koukoulis G., Kita M., et al. (2008).  Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.. Horm Metab Res. 40(4), 281-5.
Anastasilakis, A. D., Polyzos S. A., Makras P., Douni E., & Mantzoros C. S. (2019).  Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?. Metabolism. 93, 100-102.
Anastasilakis, A. D., Tsourdi E., Makras P., Polyzos S. A., Meier C., McCloskey E. V., et al. (2019).  Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society.. Bone. 127, 401-418.
Anastasilakis, D. A., Makras P., Polyzos S. A., & Anastasilakis A. D. (2019).  Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview.. Hormones (Athens). 18(1), 65-70.
Anastasilakis, A. D., Polyzos S. A., Efstathiadou Z. A., Savvidis M., Sakellariou G. T., Papatheodorou A., et al. (2015).  Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.. Metabolism. 64(10), 1291-7.
Anastasilakis, A. D., Polyzos S. A., & Makras P. (2018).  THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.. Eur J Endocrinol. 179(1), R31-R45.
Anastasilakis, A. D., Polyzos S. A., Delaroudis S., Toulis K. A., Mandanas S., Avgerinidou C., et al. (2012).  Long-term effects of thyroid fine-needle biopsy on the thyroid-related biochemical parameters.. Int J Clin Pract. 66(6), 602-9.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές